Joint with: Emerging Cell Therapies 2026
Antibodies as Drugs: Engineering and Computational Tools Enabling Clinical Advances
February 1-4, 2026 | Fairmont Banff Springs, Banff, AB, Canada
Scientific Organizers:
Paul Carter, John R. Desjarlais and E. Sally Ward
In Person
On Demand
February 1-4, 2026 | Fairmont Banff Springs, Banff, AB, Canada
Scientific Organizers:
Paul Carter, John R. Desjarlais and E. Sally Ward
Available Formats:
In Person
On Demand
Supported by the Directors' Fund
Available Formats: = In Person = On Demand
Sunday, February 1, 2026
Booking Function
Merchandise Options
Registration Options
Registration
4:00–8:00 PM
Welcome Mixer
6:00–8:00 PM
Monday, February 2, 2026
Breakfast
7:00–8:00 AM
Welcome and Keynote Address
8:00–9:00 AM
David Baker †, University of Washington
Computational Design of Proteins for Therapeutic Applications
Computational Design of Proteins for Therapeutic Applications
Computational Technologies for Antibody Design and Optimization
9:00–11:15 AM
Charlotte Deane †, University of Oxford
Computational Tools for Antibody Immunogenicity and Developability Risk Assessment
Computational Tools for Antibody Immunogenicity and Developability Risk Assessment
Peter S. Kim †, Stanford University
Unsupervised Evolution of Protein and Antibody Complexes with a Structure-Informed Language Model
Unsupervised Evolution of Protein and Antibody Complexes with a Structure-Informed Language Model
Peyton Greenside †, BigHat Biosciences
Combining Active Learning with a Rapid Synthetic Biology Platform to Design Therapeutic Antibodies
Combining Active Learning with a Rapid Synthetic Biology Platform to Design Therapeutic Antibodies
Short Talk(s) Chosen from Abstracts
Coffee Break
9:30–9:50 AM
Poster Setup
11:15–1:00 PM
On Own for Lunch
11:15–5:00 PM
Poster Viewing
1:00–10:00 PM
Symposia Spotlight 1: Late-breaking research presentations selected from abstract submissions
2:30–4:30 PM
Short Talks Chosen from Abstracts
Coffee Available
4:30–5:00 PM
Antibody Activity on Demand - Engineering Strategies to Emerging Clinical Outcomes
5:00–7:00 PM
Naoka Hironiwa †, Chugai Pharmabody Research
Antibody Activation using Ca2+ or ATP-Switches
Antibody Activation using Ca2+ or ATP-Switches
Thomas Thisted †, Sensei Biotherapeutics
VISTA Checkpoint Inhibition by pH-Selective Antibody
VISTA Checkpoint Inhibition by pH-Selective Antibody
Tommy DiRaimondo †, Janux Therapeutics
Protease-Activated anti-PSMA T Cell Engager, JANX-007
Protease-Activated anti-PSMA T Cell Engager, JANX-007
Short Talk(s) Chosen from Abstracts
Social Hour with Lite Bites
7:00–8:00 PM
Posters
7:30–10:00 PM
Tuesday, February 3, 2026
Breakfast
7:00–8:00 AM
Emerging Antibody-based Modalities and Engineering Strategies
8:00–11:00 AM
Jo L. Viney †, Seismic Therapeutic
AI/ML for Biologics Drug Discovery for Immunology
AI/ML for Biologics Drug Discovery for Immunology
James A. Wells †, University of California, San Francisco
Degraders to Attack the Cancer Surfaceomewell
Degraders to Attack the Cancer Surfaceomewell
Paul Carter, Genentech, Inc.
Engineering Antibodies to Improve High Concentration Properties for Subcutaneous Delivery
Engineering Antibodies to Improve High Concentration Properties for Subcutaneous Delivery
E. Sally Ward, University of Southampton
Targeting Subcellular Trafficking for the Generation of Therapeutics
Targeting Subcellular Trafficking for the Generation of Therapeutics
Short Talk(s) Chosen from Abstracts
Coffee Break
9:00–9:20 AM
Poster Setup
11:00–1:00 PM
On Own for Lunch
11:00–5:00 PM
Poster Viewing
1:00–10:00 PM
Career Roundtable (Joint)
3:00–4:30 PM
Coffee Available
4:30–5:00 PM
Antibody-Drug Conjugates
5:00–7:00 PM
Elaine Hurt †, AstraZeneca
Lessons Learned from 30 Years of ADC Development
Lessons Learned from 30 Years of ADC Development
Greg Thurber †, University of Michigan
Optimizing ADC Delivery by Avidity/Affinity Tuning
Optimizing ADC Delivery by Avidity/Affinity Tuning
Arthur A. Levin †, Avidity Biosciences
Antibody-Oligonucleotide Conjugates
Antibody-Oligonucleotide Conjugates
Short Talk(s) Chosen from Abstracts
Social Hour with Lite Bites
7:00–8:00 PM
Posters
7:30–10:00 PM
Wednesday, February 4, 2026
Breakfast
7:00–8:00 AM
Harnessing the Immune System with Antibodies
8:00–11:00 AM
Eric Smith †, Regeneron Pharmaceuticals, Inc.
CD28 Bispecifics for Costimulation of T Cells
CD28 Bispecifics for Costimulation of T Cells
Pamela M. Holland †, InduPro
Proximity Labeling to Identify Target Pairs for ADCs and T Cell Engagers
Proximity Labeling to Identify Target Pairs for ADCs and T Cell Engagers
John R. Desjarlais, Xencor, Inc.
T Cell Engagers
T Cell Engagers
Rony Dahan †, Weizmann Institute of Science
Recruitment of Dendritic Cells with Bispecifics / Fc Glycoengineering
Recruitment of Dendritic Cells with Bispecifics / Fc Glycoengineering
Short Talk(s) Chosen from Abstracts
Coffee Break
9:00–9:20 AM
On Own for Lunch
11:00–5:00 PM
Symposia Spotlight 2: Late-breaking research presentations selected from abstract submissions
2:30–4:30 PM
Short Talks Chosen from Abstracts
Coffee Available
4:30–5:00 PM
Experience with Antibodies Beyond Oncology
5:00–6:45 PM
Karen Silence †, ArGEN-X
Agonist MuSK Antibodies for the Treatment of Myasthenia Gravis
Agonist MuSK Antibodies for the Treatment of Myasthenia Gravis
Erica Ollmann Saphire †, La Jolla Institute for Immunology
Anti-Viral Antibodies
Anti-Viral Antibodies
Diego Alvarado †, Celldex Therapeutics
Anti-cKit Antibodies for Chronic Urticaria
Anti-cKit Antibodies for Chronic Urticaria
Short Talk(s) Chosen from Abstracts
Meeting Wrap-Up: Outcomes and Future Directions (Organizers)
6:45–7:00 PM
Social Hour with Lite Bites
7:00–8:00 PM
Entertainment
8:00–11:00 PM
Cash Bar
8:00–11:00 PM
Thursday, February 5, 2026
Departure
12:00–11:59 PM
Subscribe for Updates